114 related articles for article (PubMed ID: 20071013)
1. Impact of AdipoR1 expression on breast cancer development.
Pfeiler G; Hudelist G; Wülfing P; Mattsson B; Königsberg R; Kubista E; Singer CF
Gynecol Oncol; 2010 Apr; 117(1):134-8. PubMed ID: 20071013
[TBL] [Abstract][Full Text] [Related]
2. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies.
Jardé T; Caldefie-Chézet F; Goncalves-Mendes N; Mishellany F; Buechler C; Penault-Llorca F; Vasson MP
Endocr Relat Cancer; 2009 Dec; 16(4):1197-210. PubMed ID: 19661131
[TBL] [Abstract][Full Text] [Related]
3. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.
Adams M; Jones JL; Walker RA; Pringle JH; Bell SC
Cancer Res; 2002 Jun; 62(11):3289-97. PubMed ID: 12036947
[TBL] [Abstract][Full Text] [Related]
4. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
Wang L; Hoque A; Luo RZ; Yuan J; Lu Z; Nishimoto A; Liu J; Sahin AA; Lippman SM; Bast RC; Yu Y
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3660-6. PubMed ID: 14506155
[TBL] [Abstract][Full Text] [Related]
5. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
6. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
7. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
8. Increased estrogen receptor betacx expression during mammary carcinogenesis.
Esslimani-Sahla M; Kramar A; Simony-Lafontaine J; Warner M; Gustafsson JA; Rochefort H
Clin Cancer Res; 2005 May; 11(9):3170-4. PubMed ID: 15867209
[TBL] [Abstract][Full Text] [Related]
9. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade.
Mommers EC; Leonhart AM; Falix F; Michalides R; Meijer CJ; Baak JP; Diest PJ
J Pathol; 2001 Jul; 194(3):327-33. PubMed ID: 11439365
[TBL] [Abstract][Full Text] [Related]
10. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
[TBL] [Abstract][Full Text] [Related]
11. Tenascin-A marker for the malignant potential of preinvasive breast cancers.
Goepel C; Buchmann J; Schultka R; Koelbl H
Gynecol Oncol; 2000 Dec; 79(3):372-8. PubMed ID: 11104607
[TBL] [Abstract][Full Text] [Related]
12. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.
Tan EY; Campo L; Han C; Turley H; Pezzella F; Gatter KC; Harris AL; Fox SB
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):467-74. PubMed ID: 17255267
[TBL] [Abstract][Full Text] [Related]
13. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
14. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
15. Histological category and expression of hormone receptors in ductal carcinoma in situ of the breast.
Lebrecht A; Buchmann J; Hefler L; Lampe D; Koelbl H
Anticancer Res; 2002; 22(3):1909-11. PubMed ID: 12168892
[TBL] [Abstract][Full Text] [Related]
16. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
17. LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situ.
Baltayan A; Naritoku WY; Chaiwun B; Tsao-Wei DD; Groshen S; Hern RA; Gusterson BA; Taylor CR; Imam SA
Anticancer Res; 2002; 22(5):2933-7. PubMed ID: 12530020
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.
Roger P; Sahla ME; Mäkelä S; Gustafsson JA; Baldet P; Rochefort H
Cancer Res; 2001 Mar; 61(6):2537-41. PubMed ID: 11289127
[TBL] [Abstract][Full Text] [Related]
19. bcl-2 expression in the spectrum of preinvasive breast lesions.
Siziopikou KP; Prioleau JE; Harris JR; Schnitt SJ
Cancer; 1996 Feb; 77(3):499-506. PubMed ID: 8630957
[TBL] [Abstract][Full Text] [Related]
20. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
